M Jennifer Cheng1, B Douglas Smith2, Christopher S Hourigan3, Ivana Gojo2, Keith W Pratz2, Amanda L Blackford4, Ambereen K Mehta1, Thomas J Smith5. 1. 1 Pain and Palliative Care Service, Clinical Center, National Institutes of Health , Bethesda, Maryland. 2. 2 Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital , Baltimore, Maryland. 3. 3 Myeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute , Baltimore, Maryland. 4. 4 Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University , Baltimore, Maryland. 5. 5 Program in Palliative Medicine and Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital , Baltimore, Maryland.
Abstract
BACKGROUND: Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults, but there is limited information on survivors' quality of life (QOL) after remission. OBJECTIVE: We piloted a survey exploring patient-reported outcomes for people with AML in first complete remission (CR1) to determine whether patients felt the survey is relevant to their well-being and to summarize patient characteristics. DESIGN/MEASUREMENTS: Cross-sectional survey of a convenience sample of AML patients in CR1 assessing QOL and functioning (European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30 v 3.0), well-being (QOL-cancer survivor [QOL-CS]), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]), and anxiety and depression (hospital anxiety and depression scale [HADS]). The survey contained five open-ended questions. RESULTS: Eighteen patients completed the survey. Most felt it was completely or mostly relevant (88.8%) in describing their QOL. Participants scored well on the EORTC QLQ-C30, fatigue being the most common symptom (83%).The FACIT-Fatigue mean score was 28.7 and median score was 33.5 (normal ≥30). Two scored in the abnormal range for anxiety and one for depression on the HADS. On the QOL-CS, participants scored more than 6 out of 10 in most domains, except the subscales of distress and fear. CONCLUSIONS: The survey content and length were appropriate. Patients reported ongoing fatigue, fears of future test results, getting a second cancer, and recurrence of cancer. Survivors experience ongoing symptoms, highlighting the importance of providers performing ongoing symptom and needs assessments.
BACKGROUND:Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults, but there is limited information on survivors' quality of life (QOL) after remission. OBJECTIVE: We piloted a survey exploring patient-reported outcomes for people with AML in first complete remission (CR1) to determine whether patients felt the survey is relevant to their well-being and to summarize patient characteristics. DESIGN/MEASUREMENTS: Cross-sectional survey of a convenience sample of AMLpatients in CR1 assessing QOL and functioning (European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30 v 3.0), well-being (QOL-cancer survivor [QOL-CS]), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]), and anxiety and depression (hospital anxiety and depression scale [HADS]). The survey contained five open-ended questions. RESULTS: Eighteen patients completed the survey. Most felt it was completely or mostly relevant (88.8%) in describing their QOL. Participants scored well on the EORTC QLQ-C30, fatigue being the most common symptom (83%).The FACIT-Fatigue mean score was 28.7 and median score was 33.5 (normal ≥30). Two scored in the abnormal range for anxiety and one for depression on the HADS. On the QOL-CS, participants scored more than 6 out of 10 in most domains, except the subscales of distress and fear. CONCLUSIONS: The survey content and length were appropriate. Patients reported ongoing fatigue, fears of future test results, getting a second cancer, and recurrence of cancer. Survivors experience ongoing symptoms, highlighting the importance of providers performing ongoing symptom and needs assessments.
Entities:
Keywords:
acute myeloid leukemia; cancer survivorship; complete remission
Authors: Jennifer M Jones; Karin Olson; Pamela Catton; Charles N Catton; Neil E Fleshner; Monika K Krzyzanowska; David R McCready; Rebecca K S Wong; Haiyan Jiang; Doris Howell Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Justin C Brown; Tania B Huedo-Medina; Linda S Pescatello; Shannon M Pescatello; Rebecca A Ferrer; Blair T Johnson Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-11-04 Impact factor: 4.254
Authors: Perry Skeath; Shanti Norris; Vani Katheria; Jonathan White; Karen Baker; Dan Handel; Esther Sternberg; John Pollack; Hunter Groninger; Jayne Phillips; Ann Berger Journal: Qual Health Res Date: 2013-07-17
Authors: Alberto Redaelli; Jennifer M Stephens; Suzanne Brandt; Marc F Botteman; Chris L Pashos Journal: Cancer Treat Rev Date: 2004-02 Impact factor: 12.111
Authors: Dorle Messerer; Jutta Engel; Joerg Hasford; Markus Schaich; Gerhard Ehninger; Cristina Sauerland; Thomas Büchner; Andrea Schumacher; Rainer Krahl; Dietger Niederwieser; Jürgen Krauter; Arnold Ganser; Ursula Creutzig; Hartmut Döhner; Richard F Schlenk Journal: Haematologica Date: 2008-05-10 Impact factor: 9.941
Authors: Mohamad S Alabdaljabar; Ibrahim N Muhsen; Jennifer M Knight; Karen L Syrjala; Shahrukh K Hashmi Journal: Blood Rev Date: 2020-12-01 Impact factor: 8.250